• Homepage
  • Antibodies
  • anti-Lin-28 Homolog A (C. Elegans) (LIN28A) (AA 1-5), (N-Term) antibody

Lin-28 Homolog A (C. Elegans) (LIN28A) (AA 1-5), (N-Term) antibody

Details for Product No. ABIN783322
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Synonyms Lin28, csdd1, lin-28, lin28, zcchc1, CSDD1, LIN-28, LIN28, ZCCHC1, lin-28A, AL024421, ENSMUSG00000070700, Gm10299, Lin-28, Tex17, RGD1566408, sb:cb650, zgc:55584
Epitope
AA 1-5, N-Term
(13), (4), (3), (3), (3), (2), (2), (2), (1), (1), (1), (1)
Reactivity
Human, Mouse (Murine), Rat (Rattus)
(71), (32), (20), (13), (13), (1)
Host
Rabbit
(51), (23)
Clonality
Polyclonal
Conjugate
Un-conjugated
(1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Application
Western Blotting (WB)
(62), (31), (18), (17), (13), (10), (9), (9), (4), (3), (3)
Pubmed 3 references available
Catalog no. ABIN783322
Quantity 0.1 mL
Price
308.00 $   Plus shipping costs $45.00
Shipping to United States (Change)
Availability Will be delivered in 6 to 8 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen Peptide sequence around aa. 1~5 derived from Human Lin28
Sequence M-G-S-V-S
Specificity This antibody detects endogenous levels of total Lin28 protein. Species Reactivity: Tested: Human, Mouse, Rat
Purification Affinity-chromatography using epitope-specific peptide
Alternative Name LIN28
Background Acts as a 'translational enhancer', driving specific mRNAs to polysomes and thus increasing the efficiency of protein synthesis. Its association with the translational machinery and target mRNAs results in an increased number of initiation events per molecule of mRNA and, indirectly, in stabilizing the mRNAs. Binds IGF2 mRNA, MYOD1 mRNA, ARBP/36B4 ribosomal protein mRNA and its own mRNA. Essential for skeletal muscle differentiation program through the translational up-regulation of IGF2 expression. Acts as a suppressor of microRNA (miRNA) biogenesis by specifically binding the precursor let-7 (pre-let-7), a miRNA precursor. Acts by binding pre-let-7 and recruiting ZCCHC11/TUT4 uridylyltransferase, leading to the terminal uridylation of pre-let-7. Uridylated pre-let-7 miRNAs fail to be processed by Dicer and undergo degradation. Degradation of pre-let-7 in embryonic stem (ES) cells contributes to the maintenance of ES cells.
Alternate names: CSDD1, LIN-28, LIN28A, Lin-28 homolog A, ZCCHC1
Molecular Weight 26 kDa
Gene ID 79727
NCBI Accession NP_078950
UniProt Q9H9Z2
Restrictions For Research Use only
Format Liquid
Concentration 1.0 mg/mL
Buffer Phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Avoid repeated freezing and thawing.
Storage -20 °C
Storage Comment Store (in aliquots) at -20 °C.
Expiry Date 12 months
Background publications Heo, Joo, Cho et al.: "Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA." in: Molecular cell, Vol. 32, Issue 2, pp. 276-84, 2008 (PubMed).

Viswanathan, Powers, Einhorn et al.: "Lin28 promotes transformation and is associated with advanced human malignancies." in: Nature genetics, Vol. 41, Issue 7, pp. 843-8, 2009 (PubMed).

Heo, Joo, Kim et al.: "TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation." in: Cell, Vol. 138, Issue 4, pp. 696-708, 2009 (PubMed).

Hosts (51), (23)
Reactivities (71), (32), (20), (13), (13), (1)
Applications (62), (31), (18), (17), (13), (10), (9), (9), (4), (3), (3)
Conjugates (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Epitopes (13), (4), (3), (3), (3), (2), (2), (2), (1), (1), (1), (1)
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Validation Images
back to top